ERIS Lifesciences Ltd

About ERIS Lifesciences Ltd

ERIS Lifesciences Ltd. is a prominent Indian pharmaceutical company specializing in chronic and lifestyle-related diseases. It focuses on high-growth therapeutic areas like cardiology, diabetes, gastroenterology, and central nervous system disorders. With a strong presence in the domestic branded generics market, Eris is known for its doctor-centric approach and strategic acquisitions.

Key Financial Ratios of ERIS Lifesciences Ltd

• P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. ERIS Lifesciences Ltd's P/E ratio (TTM) is 73.82, compared to the industry median of 30.91 and large cap median of 28.64.

• P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. ERIS Lifesciences Ltd's P/B ratio is 4.61, compared to the industry median of 3.69 and large cap median of 3.11.

• P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. ERIS Lifesciences Ltd's P/S ratio is 5.60, compared to the industry median of 3.74 and large cap median of 3.02.

• PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. ERIS Lifesciences Ltd's PEG ratio is 1.70.

• EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. ERIS Lifesciences Ltd's EV/EBITDA ratio is 16.59.

• Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. ERIS Lifesciences Ltd's ROE is 16.60%.

• Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. ERIS Lifesciences Ltd's ROA is 15.20%.

• Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. ERIS Lifesciences Ltd's ROCE is 14%.

• Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. ERIS Lifesciences Ltd's operating margin is 35.79%.

• Net Margin: Net margin shows what percentage of revenue converts into final net profit. ERIS Lifesciences Ltd's net margin is 20.71%.

• Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. ERIS Lifesciences Ltd's current ratio is 0.79.

• Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. ERIS Lifesciences Ltd's debt-to-equity ratio is 0.25.

• Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. ERIS Lifesciences Ltd's interest coverage ratio is 4.31.

• Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. ERIS Lifesciences Ltd's DPS is ₹7.16.

• Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. ERIS Lifesciences Ltd's EPS is 73.07.

(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹1299.90. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")

Key Facts

• Founded: 2007

• Headquarters: Ahmedabad, Gujarat

• Core Offerings: Cardiology, Diabetes, Central Nervous System, Gastroenterology, Dermatology, Pain Management

• Stock Listing: NSE (ERIS), BSE (540596)

• Promoter: Amit Indubhushan Bakshi

History of ERIS Lifesciences Ltd

Eris Lifesciences was incorporated in 2007 by Mr. Amit Bakshi. The company rapidly established itself in the chronic therapy segments, leveraging a strong doctor-connect model. In 2017, Eris went public with an Initial Public Offering (IPO) and subsequently embarked on a series of strategic acquisitions, including Strides Shasun's domestic branded generics business (2017), Oaknet Healthcare's dermatology business (2019), Wockhardt's CV & Anti-diabetic business (2021), Biocon Biologics' domestic branded formulation business (2022), and select branded pharmaceuticals from Dr. Reddy's Laboratories (2023), significantly expanding its portfolio and market presence in the Indian pharmaceutical landscape.

Business Segments and Revenue Mix

• Chronic & Lifestyle-related Therapies: Strong focus on high-growth areas like Cardiology, Diabetes, Central Nervous System (CNS), Gastroenterology, and Dermatology, which are key drivers of its product portfolio.

• Indian Branded Generics: Operates exclusively within the Indian branded generics market, employing a large field force to build strong relationships with medical practitioners across the country.

• Strategic Acquisitions: Consistently grown its market share and product basket through synergistic acquisitions of brands and businesses from other pharmaceutical majors, enhancing its therapeutic presence and scale.

Key Personnel

Amit Indubhushan Bakshi: Chairman & Managing Director. A first-generation entrepreneur and founder of ERIS Lifesciences, he has over two decades of experience in the Indian pharmaceutical industry, having previously worked at leading pharmaceutical companies.

Subsidiaries and Associate Companies

• Eris Healthcare Private Limited

• Kinedex Healthcare Private Limited

• Oaknet Healthcare Private Limited

• Eris Pharmaceuticals Private Limited

• Eris Diagnostics Private Limited

Corporate Actions

2017: Initial Public Offering (IPO) on NSE & BSE. 2017: Acquired Strides Shasun's domestic branded generics business for ₹500 Cr. 2019: Acquired dermatology and cosmetology business of Oaknet Healthcare for ₹210 Cr. 2021: Acquired the cardiovascular and anti-diabetic division of Wockhardt Ltd. for ₹1,821 Cr. 2022: Acquired Biocon Biologics' domestic branded formulation business for ₹1,248 Cr. 2023: Acquired domestic branded pharmaceuticals business from Dr. Reddy's Laboratories for ₹1,821 Cr. 2024: Bonus Issue in ratio 1:1 (Record date: May 27, 2024).

References

1. Annual Report FY2023-24
2. Exchange Filings (NSE/BSE)
3. Company Investor Presentations
4. Financial Results Announcement